Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes

Chiba, Koki; Nomoto, Hiroshi; Nakamura, Akinobu; Cho, Kyu Yong; Yamashita, Kumiko; Shibayama, Yui; Miya, Aika; Kameda, Hiraku; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes

Chiba, Koki; Nomoto, Hiroshi; Nakamura, Akinobu et al.

Journal of diabetes investigation, 2021, 12(2), 176-183

Permalink : https://hdl.handle.net/2115/80386

このアイテムのアクセス数:580件（2026-08-24 16:09 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1111/jdi.13335			82

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/80386
タイトル	Sodium-glucose cotransporter 2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes
著者	Chiba, Koki ; Nomoto, Hiroshi ; Nakamura, Akinobu ; Cho, Kyu Yong ; Yamashita, Kumiko ; Shibayama, Yui ; Miya, Aika ; Kameda, Hiraku ; Kurihara, Yoshio ; Aoki, Shin ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名 Chiba, Koki
e-Rad_Researcher 50862330 著者名 Nomoto, Hiroshi
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
著者名 Cho, Kyu Yong
著者名 Yamashita, Kumiko
著者名 Shibayama, Yui
著者名 Miya, Aika
e-Rad_Researcher 20826127 著者名 Kameda, Hiraku
著者名 Kurihara, Yoshio
著者名 Aoki, Shin
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
言語	英語
キーワード	Glucose variability
	Sodium-glucose cotransporter 2 inhibitor
	Type 1 diabetes
発行日	2021-02
出版者	John Wiley & Sons
収録物名	Journal of diabetes investigation
巻(号)	12(2)
ページ	176-183
抄録	Aims/Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are used worldwide because of their multiple benefits for patients with type 2 diabetes. The purpose of this study was to determine the efficacy and safety of SGLT2i in patients with type 1 diabetes. Materials and Methods Patients with type 1 diabetes who had been treated with SGLT2i for >12 weeks were included in this retrospective observation study. We recorded the changes in body mass, insulin dose, blood and urine test data, and adverse events. The changes in day-to-day glucose variability, as the primary end-point, was evaluated using the interquartile range (P25/P75) of the ambulatory glucose data obtained using continuous glucose monitoring. Results A total of 51 patients (37 women; mean age 52.7 years) were included. Glycated hemoglobin and body mass significantly decreased by 0.4% and 1.6 kg, respectively. The total required insulin dose decreased by 9.4% (42.7 +/- 26.6-38.7 +/- 24.3 units/day). Continuous glucose monitoring data were obtained from 30 patients. P25/P75 decreased by 17.6 +/- 20.7% during SGLT2i treatment (P < 0.001). The percentage of time per day within the target glucose range of 70-180 mg/dL significantly increased (from 42.2 to 55.5%,P < 0.001), without an increase in the percentage of time spent in the hypoglycemic range (<70 mg/dL). Urinary ketone bodies were detected in four patients (7.8%), but none developed ketoacidosis. Conclusions SGLT2i improved day-to-day glucose variability and time in the target glucose range, without increasing frequency of hypoglycemia, in patients with type 1 diabetes, and reduced glycated hemoglobin, body mass and the required insulin dose.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	2040-1116
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1111/jdi.13335